KR100704319B1 - 고선택성 노르에피네프린 재흡수 억제제 및 그의 이용 방법 - Google Patents

고선택성 노르에피네프린 재흡수 억제제 및 그의 이용 방법 Download PDF

Info

Publication number
KR100704319B1
KR100704319B1 KR1020017016963A KR20017016963A KR100704319B1 KR 100704319 B1 KR100704319 B1 KR 100704319B1 KR 1020017016963 A KR1020017016963 A KR 1020017016963A KR 20017016963 A KR20017016963 A KR 20017016963A KR 100704319 B1 KR100704319 B1 KR 100704319B1
Authority
KR
South Korea
Prior art keywords
reboxetine
disorders
delete delete
norepinephrine
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020017016963A
Other languages
English (en)
Korean (ko)
Other versions
KR20020015363A (ko
Inventor
에릭 에이취. 에프. 웡
사에두딘 아흐메드
로버트 클라이드 마샬
로버트 맥아더
던컨 피. 테일러
라스 버거슨
파스쿠알레 세테라
Original Assignee
파마시아 앤드 업존 캄파니 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27495506&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR100704319(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 파마시아 앤드 업존 캄파니 엘엘씨 filed Critical 파마시아 앤드 업존 캄파니 엘엘씨
Publication of KR20020015363A publication Critical patent/KR20020015363A/ko
Application granted granted Critical
Publication of KR100704319B1 publication Critical patent/KR100704319B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020017016963A 1999-07-01 2000-06-22 고선택성 노르에피네프린 재흡수 억제제 및 그의 이용 방법 Expired - Fee Related KR100704319B1 (ko)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US14196899P 1999-07-01 1999-07-01
US60/141,968 1999-07-01
US14413199P 1999-07-16 1999-07-16
US60/144,131 1999-07-16
US15825699P 1999-10-06 1999-10-06
US60/158,256 1999-10-06
US17038199P 1999-12-13 1999-12-13
US60/170,381 1999-12-13

Related Child Applications (2)

Application Number Title Priority Date Filing Date
KR1020067017835A Division KR100935277B1 (ko) 1999-07-01 2000-06-22 고선택성 노르에피네프린 재흡수 억제제 및 그의 이용 방법
KR1020057009371A Division KR100717660B1 (ko) 1999-07-01 2000-06-22 고선택성 노르에피네프린 재흡수 억제제 및 그의 이용 방법

Publications (2)

Publication Number Publication Date
KR20020015363A KR20020015363A (ko) 2002-02-27
KR100704319B1 true KR100704319B1 (ko) 2007-04-09

Family

ID=27495506

Family Applications (5)

Application Number Title Priority Date Filing Date
KR1020017016963A Expired - Fee Related KR100704319B1 (ko) 1999-07-01 2000-06-22 고선택성 노르에피네프린 재흡수 억제제 및 그의 이용 방법
KR1020067017835A Expired - Fee Related KR100935277B1 (ko) 1999-07-01 2000-06-22 고선택성 노르에피네프린 재흡수 억제제 및 그의 이용 방법
KR1020057009371A Expired - Fee Related KR100717660B1 (ko) 1999-07-01 2000-06-22 고선택성 노르에피네프린 재흡수 억제제 및 그의 이용 방법
KR1020097015714A Ceased KR20090087135A (ko) 1999-07-01 2000-06-22 고선택성 노르에피네프린 재흡수 억제제 및 그의 이용 방법
KR1020097015713A Expired - Fee Related KR100948757B1 (ko) 1999-07-01 2000-06-22 고선택성 노르에피네프린 재흡수 억제제 및 그의 이용 방법

Family Applications After (4)

Application Number Title Priority Date Filing Date
KR1020067017835A Expired - Fee Related KR100935277B1 (ko) 1999-07-01 2000-06-22 고선택성 노르에피네프린 재흡수 억제제 및 그의 이용 방법
KR1020057009371A Expired - Fee Related KR100717660B1 (ko) 1999-07-01 2000-06-22 고선택성 노르에피네프린 재흡수 억제제 및 그의 이용 방법
KR1020097015714A Ceased KR20090087135A (ko) 1999-07-01 2000-06-22 고선택성 노르에피네프린 재흡수 억제제 및 그의 이용 방법
KR1020097015713A Expired - Fee Related KR100948757B1 (ko) 1999-07-01 2000-06-22 고선택성 노르에피네프린 재흡수 억제제 및 그의 이용 방법

Country Status (30)

Country Link
US (18) US6465458B1 (enExample)
EP (3) EP2090312A1 (enExample)
JP (3) JP2003503450A (enExample)
KR (5) KR100704319B1 (enExample)
CN (5) CN1289090C (enExample)
AR (1) AR035158A1 (enExample)
AT (9) ATE305307T1 (enExample)
AU (2) AU771258B2 (enExample)
BR (1) BR0012136A (enExample)
CA (2) CA2375908C (enExample)
CL (3) CL2008002866A1 (enExample)
CO (1) CO5190662A1 (enExample)
CZ (1) CZ299847B6 (enExample)
DE (9) DE60019473T2 (enExample)
DK (4) DK1459750T3 (enExample)
EA (6) EA005029B1 (enExample)
ES (9) ES2285645T3 (enExample)
GE (1) GEP20094798B (enExample)
HU (1) HUP0201623A3 (enExample)
IL (3) IL147246A0 (enExample)
MX (1) MXPA02000562A (enExample)
MY (1) MY137348A (enExample)
NO (4) NO20016406L (enExample)
NZ (2) NZ515885A (enExample)
PE (1) PE20010684A1 (enExample)
PL (1) PL196996B1 (enExample)
PT (5) PT1459751E (enExample)
SK (5) SK286669B6 (enExample)
TW (9) TW200920378A (enExample)
WO (1) WO2001001973A2 (enExample)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60019473T2 (de) * 1999-07-01 2006-02-23 Pharmacia & Upjohn Co. Llc, Kalamazoo (S,S)-Reboxetin zur Behandlung von peripheren Neuropathien
MXPA02005275A (es) * 1999-12-01 2003-02-17 Ucb Sa Derivado de pirrolidinacetamida solo en combinacion para el tratamiento de trastornos del sistema nervioso central.
JP2004502650A (ja) 2000-04-21 2004-01-29 ファルマシア・アンド・アップジョン・カンパニー 線維筋痛症候群および慢性疲労症候群を治療するための化合物
CA2404704A1 (en) * 2000-04-21 2001-11-22 David W. Robertson Treatment of fibromyalgia and chronic fatigue syndrome
US20040048860A1 (en) * 2000-10-31 2004-03-11 Jes Olesen Use of selective noradrenaline reuptake inhibitors for the treatment of tension-type headache
EP1395253A2 (en) * 2000-11-15 2004-03-10 Eli Lilly And Company Treatment of anxiety disorders
WO2002083141A1 (en) * 2001-04-17 2002-10-24 Pharmacia & Upjohn Company Treatment of fibromyalgia and chronic fatigue syndrome
US20040048874A1 (en) * 2001-05-22 2004-03-11 Bardsley Hazel Judith New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine
GB0216027D0 (en) * 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
SI1627639T1 (sl) * 2001-06-19 2010-04-30 Mueller Norbert Uporaba inhibitorjev COX-2 za zdravljenje afektivnih motenj
US20060167074A1 (en) * 2001-06-19 2006-07-27 Norbert Muller Methods and compositions for the treatment of psychiatric disorders
US6602911B2 (en) 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
AU2002347984A1 (en) * 2001-11-30 2003-06-17 Eli Lilly And Company Use of norepinephrine reuptake inhibitors for the treatment of tic disorders
EA200400793A1 (ru) * 2001-12-11 2004-10-28 Эли Лилли Энд Компани Применение ингибиторов обратного захвата норэпинефрина для лечения нарушения познавательной функции
US20040102440A1 (en) * 2002-07-01 2004-05-27 Wong Erik Ho Fong Method of promoting smoking cessation
AU2003213009A1 (en) * 2002-02-12 2003-09-04 Cypress Bioscience, Inc. Methods of treating attention deficit/hyperactivity disorder (adhd)
EP1499309A4 (en) * 2002-04-24 2008-05-28 Cypress Bioscience Inc PREVENTION AND TREATMENT OF FUNCTIONAL SOMATIC DISEASES, INCLUDING STRESS-BASED DISEASES
KR20110043664A (ko) * 2002-05-17 2011-04-27 듀크 유니버시티 비만치료방법
AU2003227520B9 (en) * 2002-05-30 2008-06-26 Neurosearch A/S Triple monoamine reuptake inhibitors for the treatment of chronic pain
WO2003106441A1 (en) * 2002-06-17 2003-12-24 Pharmacia Italia S.P.A. Pharmaceutical salts of reboxetine
MY136318A (en) * 2002-07-25 2008-09-30 Pharmacia Corp Sustained-release tablet composition
US20050226926A1 (en) 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
KR20050049476A (ko) * 2002-08-14 2005-05-25 파마시아 앤드 업존 캄파니 엘엘씨 홍조를 치료하기 위한 레복세틴의 용도
EP1546123B1 (en) 2002-08-23 2006-05-31 Eli Lilly And Company Benzyl morpholine derivatives
AU2003269923A1 (en) 2002-08-23 2004-03-11 Eli Lilly And Company 2- (phenoxymethyl)- and 2- (phenylthiomethyl)-morpholine derivatives for use as selective norepinephrine reuptake inhibitors
GB0219687D0 (en) 2002-08-23 2002-10-02 Lilly Co Eli Benzyl morpholine derivatives
EP1558231A4 (en) * 2002-10-03 2010-09-08 Cypress Bioscience Inc DOSAGE CLIMBING AND FRICTIONAL DAILY DOSE OF ANTIDEPRESSANTS TO TREAT NEUROLOGICAL DISORDERS
US7345096B2 (en) * 2002-10-15 2008-03-18 Wyeth Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
US20040152710A1 (en) * 2002-10-15 2004-08-05 Deecher Darlene Coleman Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
US20040180879A1 (en) * 2002-10-15 2004-09-16 Deecher Darlene Coleman Novel method of treating vasomotor symptoms
US20040204411A1 (en) * 2002-12-17 2004-10-14 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
DE602004005814T2 (de) * 2003-01-13 2008-01-10 Dynogen Pharmaceuticals Inc., Waltham Verfahren zur behandlung von übelkeit, erbrechen, würgereiz oder jede kombination daraus
EP1558081A4 (en) * 2003-01-13 2006-06-14 Dynogen Pharmaceuticals Inc METHOD FOR THE TREATMENT OF FUNCTIONAL ENDURANCE DISEASES
JP2006522144A (ja) * 2003-04-04 2006-09-28 ダイノゲン ファーマシューティカルズ，インコーポレイテッド 下部尿路障害の治療方法
ATE388698T1 (de) 2003-04-29 2008-03-15 Orexigen Therapeutics Inc Zusammensetzungen zur beeinflussung des gewichtsverlusts
US8158149B2 (en) * 2004-05-12 2012-04-17 Chelsea Therapeutics, Inc. Threo-DOPS controlled release formulation
WO2004100929A1 (en) 2003-05-12 2004-11-25 Synergia Pharma, Inc. Threo-dops controlled release formulation
WO2004105690A2 (en) * 2003-05-23 2004-12-09 Cypress Bioscience, Inc. Treatment of chronic pain associated with drug or radiation therapy
GB0319793D0 (en) 2003-08-22 2003-09-24 Lilly Co Eli Pyridinylmorpholine derivatives
EP1660065A2 (en) * 2003-08-27 2006-05-31 Eli Lilly And Company Treatment of pervasive developmental disorders with norepinephrine reuptake inhibitors
WO2005025561A1 (en) * 2003-09-04 2005-03-24 Synergia Pharma, Inc. Compositions and methods for orthostatic intolerance
JP2007505097A (ja) * 2003-09-12 2007-03-08 ファイザー・インク アルファ−２−デルタリガンドとセロトニン／ノルアドレナリン再取込み阻害薬を含む組合せ
US20050130987A1 (en) * 2003-10-14 2005-06-16 Wyeth Methods of treating vasomotor symptoms
US7524846B2 (en) 2003-10-14 2009-04-28 Wyeth Arylalkyl- and cycloalkylalkyl-piperazine derivatives and methods of their use
US7402698B2 (en) 2003-10-14 2008-07-22 Wyeth Secondary amino-and cycloamino-cycloalkanol derivatives and methods of their use
US7419980B2 (en) 2003-10-14 2008-09-02 Wyeth Fused-aryl and heteroaryl derivatives and methods of their use
US7531543B2 (en) 2003-10-14 2009-05-12 Wyeth Phenylpiperazine cycloalkanol derivatives and methods of their use
US7491723B2 (en) 2003-10-14 2009-02-17 Wyeth Alkanol and cycloalkanol-amine derivatives and methods of their use
US7365076B2 (en) 2003-10-14 2008-04-29 Wyeth Substituted aryl cycloalkanol derivatives and methods of their use
US7550485B2 (en) * 2003-10-14 2009-06-23 Wyeth Substituted N-heterocycle derivatives and methods of their use
GB0326148D0 (en) 2003-11-10 2003-12-17 Lilly Co Eli Morpholine derivatives
DE602004014823D1 (de) * 2003-12-12 2008-08-14 Lilly Co Eli Selektive norepinephrin-wiederaufnahmehemmer zur behandlung von hitzewallungen
WO2005066144A1 (en) * 2003-12-23 2005-07-21 Eli Lilly And Company Morpholine derivatives as norepinephrine reuptake inhibitors
US7414052B2 (en) 2004-03-30 2008-08-19 Wyeth Phenylaminopropanol derivatives and methods of their use
US7517899B2 (en) * 2004-03-30 2009-04-14 Wyeth Phenylaminopropanol derivatives and methods of their use
GB0409744D0 (en) * 2004-04-30 2004-06-09 Pfizer Ltd Novel compounds
WO2005105763A1 (en) * 2004-04-30 2005-11-10 Warner-Lambert Company Llc Substituted morpholine compounds for the treatment of central nervous system disorders
KR100871272B1 (ko) * 2004-04-30 2008-11-28 화이자 인코포레이티드 모폴린 화합물
US20080261984A1 (en) * 2004-06-09 2008-10-23 Pfizer Inc. Use of S,S-Reboxetine in the Treatment of Pain
US7244765B2 (en) * 2004-06-25 2007-07-17 Cytokine Pharmasciences, Inc Guanylhydrazone salts, compositions, processes of making and methods of using
US20090227562A1 (en) * 2004-08-10 2009-09-10 Pfizer Inc. Combination of a Selective Noradrenaline Reuptake Unhibitor and a PDEV Inhibitor
ATE486588T1 (de) 2004-08-13 2010-11-15 Boehringer Ingelheim Int Tablettenformulierung mit verlängerter freisetzung mit pramipexol oder einem pharmazeutisch zulässigen salz davon, herstellungsverfahren und verwendung dafür
WO2006038084A1 (en) * 2004-10-01 2006-04-13 Neurocure Ltd Use of pharmaceutical compositions of lofepramine for the treatment of adhd, cfs, fm and depression
US20060293309A1 (en) * 2005-03-28 2006-12-28 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
CN101370488B (zh) 2005-11-22 2012-07-18 奥雷西根治疗公司 增加胰岛素敏感性的组合物
US20070253994A1 (en) * 2006-04-28 2007-11-01 Medtronic, Inc. Intraspinal Drug Delivery Methods and Devices To Alleviate Chronic Pelvic Pain
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
ES2571730T3 (es) * 2006-06-28 2016-05-26 Lundbeck Na Ltd Composiciones farmacéuticas que comprenden droxidopa
WO2008060964A2 (en) 2006-11-09 2008-05-22 Orexigen Therapeutics, Inc. Unit dosage package and methods for administering weight loss medications
US8008285B2 (en) 2007-03-09 2011-08-30 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of fibromyalgia
WO2008122019A1 (en) * 2007-04-02 2008-10-09 Cypress Biosciences, Inc. Improving the tolerability of both mirtazapine and reboxetine by using them in combination
CN101720186A (zh) * 2007-04-30 2010-06-02 阿得罗公司 (-)-e-10-oh-nt组合物及其合成与使用的方法
NZ581707A (en) * 2007-05-07 2011-05-27 Chelsea Therapeutics Inc Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders
US8580776B2 (en) * 2007-07-10 2013-11-12 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating neurodegenerating diseases
US20090233957A1 (en) * 2008-02-19 2009-09-17 Adolor Corporation (-)-beloxepin and methods for its synthesis and use
US20090233959A1 (en) * 2008-02-19 2009-09-17 Adolor Corporation Beloxepin and analogs for the treatment of pain
US8475823B2 (en) 2008-04-18 2013-07-02 Medtronic, Inc. Baclofen formulation in a polyorthoester carrier
US8956642B2 (en) 2008-04-18 2015-02-17 Medtronic, Inc. Bupivacaine formulation in a polyorthoester carrier
MX2010012909A (es) 2008-05-30 2011-02-25 Orexigen Therapeutics Inc Metodos para tratamiento de condiciones de grasa visceral.
ES2434250T3 (es) 2008-07-24 2013-12-16 Theravance, Inc. Compuestos de 3-(fenoxifenilmetil)pirrolidina
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine
WO2010044016A1 (en) * 2008-10-17 2010-04-22 Pfizer Limited Novel uses for esreboxetine and racemic reboxetine
US20100267743A1 (en) * 2009-04-15 2010-10-21 Stangeland Eric L 3-(phenoxypyrrolidin-3-yl-methyl)heteroaryl, 3-(phenylpyrrolidin-3-ylmethoxy)heteroaryl, and 3-(heteroarylpyrrolidin-3-ylmethoxy)heteroaryl compounds
CN102471258A (zh) 2009-07-13 2012-05-23 施万制药 3-苯氧基甲基吡咯烷化合物
ES2495366T3 (es) 2009-07-21 2014-09-17 Theravance, Inc. Compuestos de 3-fenoximetilpirrolidina
JP6196041B2 (ja) 2010-01-11 2017-09-13 オレキシジェン・セラピューティクス・インコーポレーテッド 大うつ病を有する患者において減量療法を提供する方法
ES2533434T3 (es) 2010-10-11 2015-04-10 Theravance Biopharma R&D Ip, Llc Inhibidores de la captación de la serotonina
WO2012075239A1 (en) 2010-12-03 2012-06-07 Theravance, Inc. Serotonin reuptake inhibitors
JP5880913B2 (ja) 2011-05-17 2016-03-09 三郎 佐古田 パーキンソン病の体幹症状（姿勢反射異常）の治療剤
PE20150358A1 (es) 2012-06-06 2015-04-06 Orexigen Therapeutics Inc Metodos para el tratamiento del sobrepeso y de la obesidad
WO2016077724A1 (en) 2014-11-13 2016-05-19 University Of Pittsburgh - Of The Commonwealth System Of Higher Education (2-amino-4(arylamino)phenyl) carbamates
US20190381056A1 (en) 2018-06-17 2019-12-19 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
US11020402B2 (en) 2018-10-15 2021-06-01 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
WO2021113163A1 (en) * 2019-12-03 2021-06-10 Axsome Therapeutics, Inc. Use of reboxetine to treat nervous system disorders
US20200147093A1 (en) 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
EP3693020A1 (en) * 2019-02-08 2020-08-12 Burmaster International Group GmbH Potassium enriched topical formulations for pain relief and sleep aid
MX2022006630A (es) * 2019-12-03 2022-06-24 Axsome Therapeutics Inc Uso de reboxetina para tratar los trastornos del sistema nervioso.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999015177A1 (en) * 1997-09-23 1999-04-01 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
WO1999015163A1 (en) * 1997-09-23 1999-04-01 Eli Lilly And Company Treatment of conduct disorder
WO1999015176A1 (en) * 1997-09-23 1999-04-01 Eli Lilly And Company Treatment of oppositional defiant disorder

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3797494A (en) 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3742951A (en) 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US3996934A (en) 1971-08-09 1976-12-14 Alza Corporation Medical bandage
US4031894A (en) 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
IL56369A (en) 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
US4465458A (en) * 1980-03-19 1984-08-14 Matsushita Electric Industrial Co., Ltd. Apparatus for burning liquid fuel equipped with heating-type fuel vaporizer
GB8419683D0 (en) 1984-08-02 1984-09-05 Erba Farmitalia 3-substituted derivatives of 1-amino-2-hydroxy-propane
GB2167407B (en) * 1984-11-22 1988-05-11 Erba Farmitalia Enantiomers of phenoxy derivatives of benzyl morpholine and salts thereof
US4596807A (en) 1985-03-26 1986-06-24 Serotonin Industries Of Charleston Method and compositions for controlling pain, depression and sedation
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
ZA921292B (en) 1991-02-25 1993-08-23 Lilly Co Eli Treatment of lower urinary tract disorders.
US5281624A (en) 1991-09-27 1994-01-25 Eli Lilly And Company N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof
US5192751A (en) 1992-07-24 1993-03-09 Eli Lilly And Company Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence
TW344661B (en) 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
IL111786A0 (en) 1993-12-01 1995-01-24 Max Planck Gesellschaft Methods of promoting the survival and differentiation of subclasses of cholinergic and serotonergic neurons using fibroblast growth factor-5
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
ZA958725B (en) 1994-10-20 1997-04-16 Lilly Co Eli Treatment of disorders with duloxetine
JP2000507544A (ja) 1996-03-25 2000-06-20 イーライ・リリー・アンド・カンパニー 痛みの治療方法
CA2250187A1 (en) 1996-03-25 1997-10-02 Eli Lilly And Company Composition comprising olanzapine and a drug useful in the treatment of pain for use in the treatment of pain
US5914333A (en) * 1996-07-31 1999-06-22 Novo Nordisk A/S Treatment of psychotic disorders
US6572880B2 (en) * 1996-10-24 2003-06-03 Pharmaceutical Applications Associates Llc Methods and transdermal compositions for pain relief
US6479074B2 (en) * 1996-10-24 2002-11-12 Pharmaceutical Applications Associates Llc Methods and transdermal compositions for pain relief
US6290986B1 (en) * 1996-10-24 2001-09-18 Pharmaceutical Applications Associates, Llc Method and composition for transdermal administration of pharmacologic agents
US20020015713A1 (en) * 1996-10-24 2002-02-07 Murdock Robert W. Methods and transdermal compositions for pain relief
EP0856312B1 (de) 1996-11-27 1998-10-14 Dr. R. Pfleger Chemische Fabrik GmbH Verwendung von Trospiumchlorid zur Herstellung eines Arzneimittels zur Behandlung von Blasenkrankheiten
KR20000057548A (ko) 1996-12-13 2000-09-25 알프레드 엘. 미첼슨 광학적 전송물질 및 결합재
AU6966998A (en) 1997-04-11 1998-11-11 Eli Lilly And Company Composition for treating pain
AU5155198A (en) 1997-08-28 1999-03-22 Robert Murdock Method and composition for transdermal administration of pharmacologic agent
US5942530A (en) 1997-08-28 1999-08-24 Eli Lilly And Company Method for treating pain
US6622036B1 (en) * 2000-02-09 2003-09-16 Cns Response Method for classifying and treating physiologic brain imbalances using quantitative EEG
ZA989251B (en) 1997-10-17 2000-04-10 Lilly Co Eli Potentiation of pharmaceuticals.
US6586427B2 (en) * 1998-04-09 2003-07-01 Pharmacia & Upjohn Company Treatments for nervous disorders
IL138855A0 (en) 1998-04-09 2001-10-31 Upjohn Co New treatments for nervous disorders
IT1305322B1 (it) 1998-04-23 2001-05-04 Pharmacia & Upjohn Spa Uso di reboxetina per il trattamento di disturbi nervosi
PT1075264E (pt) 1998-05-08 2005-01-31 Upjohn Co Novas combinacoes farmacologicas de reboxetina e pindolol
EP1093348A4 (en) 1998-06-29 2003-07-16 Pharmaceuticals Applic Asociat TRANSDERMAL ANALGESIC COMPOSITIONS AND METHODS OF ADMINISTRATION
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
DE60019473T2 (de) 1999-07-01 2006-02-23 Pharmacia & Upjohn Co. Llc, Kalamazoo (S,S)-Reboxetin zur Behandlung von peripheren Neuropathien
GB2355191A (en) * 1999-10-12 2001-04-18 Laxdale Ltd Combination formulations for fatigue, head injury and strokes
SE9904750D0 (sv) 1999-12-23 1999-12-23 Pharmacia & Upjohn Ab New formulation, use and method
PT1257277E (pt) 2000-02-24 2005-09-30 Pharmacia & Upjohn Co Llc Novas combinacoes de farmacos
US20050096349A1 (en) * 2003-11-03 2005-05-05 University Of Florida Methods to prevent or ameliorate medication-, procedure-or stress-induced cognitive and speech dysfunction and methods to optimize cognitive and speech functioning

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999015177A1 (en) * 1997-09-23 1999-04-01 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
WO1999015163A1 (en) * 1997-09-23 1999-04-01 Eli Lilly And Company Treatment of conduct disorder
WO1999015176A1 (en) * 1997-09-23 1999-04-01 Eli Lilly And Company Treatment of oppositional defiant disorder

Also Published As

Publication number Publication date
SK286864B6 (sk) 2009-06-05
US7276503B2 (en) 2007-10-02
HK1076723A1 (en) 2006-01-27
US7723334B2 (en) 2010-05-25
MXPA02000562A (es) 2002-07-02
WO2001001973A8 (en) 2001-05-17
ES2247572T3 (es) 2006-03-01
US20060264436A1 (en) 2006-11-23
NO20091158L (no) 2002-02-19
WO2001001973A2 (en) 2001-01-11
TW200407146A (en) 2004-05-16
PT1459748E (pt) 2005-08-31
TW200922594A (en) 2009-06-01
US7338953B2 (en) 2008-03-04
CL2008002867A1 (es) 2009-01-09
US20060128705A1 (en) 2006-06-15
EA011094B1 (ru) 2008-12-30
DE60022917D1 (de) 2006-02-09
US6987107B2 (en) 2006-01-17
US6703389B2 (en) 2004-03-09
ATE296634T1 (de) 2005-06-15
AU771258B2 (en) 2004-03-18
CL2008002866A1 (es) 2009-01-09
DE60022692D1 (de) 2005-10-20
DE60022916D1 (de) 2006-02-09
ES2258010T3 (es) 2006-08-16
US6610690B2 (en) 2003-08-26
US20040147614A1 (en) 2004-07-29
DE60026627D1 (de) 2006-05-04
DK1196172T3 (da) 2006-06-19
CA2375908A1 (en) 2001-01-11
DE60026627T2 (de) 2007-02-01
DE60035232D1 (de) 2007-07-26
DE60023043D1 (de) 2006-02-16
IL147246A0 (en) 2002-08-14
TWI298255B (en) 2008-07-01
ATE305788T1 (de) 2005-10-15
PE20010684A1 (es) 2001-06-24
CA2375908C (en) 2006-05-30
MY137348A (en) 2009-01-30
DE60022916T2 (de) 2006-07-06
JP2006321815A (ja) 2006-11-30
DE60035232T2 (de) 2008-02-14
DE60022917T2 (de) 2006-06-29
EP2090312A1 (en) 2009-08-19
NO20091159L (no) 2002-02-19
HK1049630A1 (en) 2003-05-23
US20020128173A1 (en) 2002-09-12
ES2246488T3 (es) 2006-02-16
IL187512A0 (en) 2008-06-05
US20080103147A1 (en) 2008-05-01
NO20016406L (no) 2002-02-19
DK1459749T3 (da) 2006-01-09
US20060135521A1 (en) 2006-06-22
PT1459750E (pt) 2005-08-31
TWI294779B (en) 2008-03-21
TW200607510A (en) 2006-03-01
US20020061910A1 (en) 2002-05-23
SK286667B6 (sk) 2009-03-05
TWI293250B (en) 2008-02-11
GEP20094798B (en) 2009-10-26
NZ533243A (en) 2005-12-23
PL196996B1 (pl) 2008-02-29
TWI245631B (en) 2005-12-21
AU2004202096B2 (en) 2005-10-20
US20080103146A1 (en) 2008-05-01
DK1632234T3 (da) 2007-09-17
US20080103145A1 (en) 2008-05-01
CA2643231A1 (en) 2001-01-11
US7241762B2 (en) 2007-07-10
CN1660110A (zh) 2005-08-31
CN1205935C (zh) 2005-06-15
AU2004202096A1 (en) 2004-06-10
EA008381B1 (ru) 2007-04-27
US20030040464A1 (en) 2003-02-27
CN1660108A (zh) 2005-08-31
TWI298254B (en) 2008-07-01
PT1196172E (pt) 2006-05-31
ATE305307T1 (de) 2005-10-15
KR20090087135A (ko) 2009-08-14
ATE304358T1 (de) 2005-09-15
KR20060099544A (ko) 2006-09-19
EP2087892A2 (en) 2009-08-12
BR0012136A (pt) 2002-06-11
TW200607511A (en) 2006-03-01
KR20090087134A (ko) 2009-08-14
US20020107249A1 (en) 2002-08-08
ATE305306T1 (de) 2005-10-15
PL352252A1 (en) 2003-08-11
SK286104B6 (sk) 2008-03-05
EA200200111A1 (ru) 2002-06-27
ATE364386T1 (de) 2007-07-15
CO5190662A1 (es) 2002-08-29
NZ515885A (en) 2004-08-27
ES2246487T3 (es) 2006-02-16
US20060142289A1 (en) 2006-06-29
ES2285645T3 (es) 2007-11-16
DE60020613T2 (de) 2006-03-16
AU5633700A (en) 2001-01-22
KR100948757B1 (ko) 2010-03-23
CN1660109A (zh) 2005-08-31
US20020086864A1 (en) 2002-07-04
US20040058925A1 (en) 2004-03-25
DE60023043T2 (de) 2006-06-14
KR20050053799A (ko) 2005-06-08
DK1459750T3 (da) 2005-08-15
ATE292971T1 (de) 2005-04-15
DE60019473D1 (de) 2005-05-19
TW200920378A (en) 2009-05-16
EA200801805A1 (ru) 2008-12-30
US20080096890A1 (en) 2008-04-24
DE60020613D1 (de) 2005-07-07
JP2003503450A (ja) 2003-01-28
SK286668B6 (sk) 2009-03-05
HUP0201623A2 (en) 2002-09-28
CL2008002868A1 (es) 2009-01-09
DE60019473T2 (de) 2006-02-23
ES2246485T3 (es) 2006-02-16
ES2239311T3 (es) 2005-09-16
CZ299847B6 (cs) 2008-12-10
KR20020015363A (ko) 2002-02-27
NO20016406D0 (no) 2001-12-28
TW200607512A (en) 2006-03-01
CN1289090C (zh) 2006-12-13
US20060135520A1 (en) 2006-06-22
US6642235B2 (en) 2003-11-04
EA200700232A1 (ru) 2007-06-29
EP1196172A2 (en) 2002-04-17
EA006652B1 (ru) 2006-02-24
EA200501496A1 (ru) 2006-06-30
AR035158A1 (es) 2004-05-05
ES2258251T3 (es) 2006-08-16
KR100717660B1 (ko) 2007-05-15
PT1632234E (pt) 2007-07-09
CZ20014625A3 (cs) 2002-08-14
CN1660111A (zh) 2005-08-31
US6465458B1 (en) 2002-10-15
EA005029B1 (ru) 2004-10-28
CN1379672A (zh) 2002-11-13
US7317011B2 (en) 2008-01-08
TW200607509A (en) 2006-03-01
HUP0201623A3 (en) 2004-12-28
SK19382001A3 (sk) 2002-07-02
EA200801806A1 (ru) 2008-12-30
DE60026704T2 (de) 2006-10-19
ATE320257T1 (de) 2006-04-15
JP2006143749A (ja) 2006-06-08
WO2001001973A3 (en) 2002-01-17
DE60022692T2 (de) 2006-06-22
EP2087892A3 (en) 2009-09-30
EP1196172B1 (en) 2006-03-15
SK286669B6 (sk) 2009-03-05
PT1459751E (pt) 2005-11-30
IL187513A0 (en) 2008-06-05
NO20091168L (no) 2002-02-19
EA200400589A1 (ru) 2004-12-30
ES2242175T3 (es) 2005-11-01
US20090247528A1 (en) 2009-10-01
DE60026704D1 (de) 2006-05-11
TW200914027A (en) 2009-04-01
ATE319453T1 (de) 2006-03-15
KR100935277B1 (ko) 2010-01-06

Similar Documents

Publication Publication Date Title
KR100704319B1 (ko) 고선택성 노르에피네프린 재흡수 억제제 및 그의 이용 방법
EP1632234B1 (en) (S,S)-reboxetine for treating chronic fatigue syndrome
CN1969859A (zh) 高度选择性去甲肾上腺素再摄取抑制剂及其用途
HK1103019A (en) Highly selective norepinephrine reuptake inhibitors and methods of using the same

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A107 Divisional application of patent
A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

A107 Divisional application of patent
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20100122

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20110331

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20110331

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000